10
Participants
Start Date
March 31, 2007
Primary Completion Date
March 31, 2008
Study Completion Date
March 31, 2008
CAP-232
Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period
CRLC Val d'Aurelle Paul-Lamarque, Montpellier
Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez
Lead Sponsor
Thallion Pharmaceuticals
INDUSTRY